glp-1 npa Cardiovascular Protection with a Long-Acting Receptor Agonist Liraglutide: An Experimental Update Prescription GLP-1s for Weight Loss
Description
They can increase bloating and discomfort when digestion is already slowed
There are no FDA-approved generic versions of these three drugs, and there are no other FDA-approved semaglutide products
A report from PricewaterhouseCoopers found that GLP-1 drugs drove a disproportionate share of the $50 billion hike in pharmacy spending in 2024 (up from a $20 billion increase in 2023)
Candidacy for GLP-1 weight loss treatment is typically determined based on current body weight (BMI), metabolic health markers, medical history, and personal weight loss goals
Inflammation is a common thread linking cardiovascular disease, aging, neurodegeneration and metabolic dysfunction
